MVA-BN standard regimen + MVA-BN standard regimen (Administered as PEP)
Phase 3Active 1 views this week 0 watching⚡ Active
Interest: 41/100
41
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Neonate
Conditions
Neonate, Maternal Transmission, Mpox, Vaccination, Immunogenicity, Safety, Pregnancy, Postpartum
Trial Timeline
Jun 23, 2025 → May 1, 2027
NCT ID
NCT06844500About MVA-BN standard regimen + MVA-BN standard regimen (Administered as PEP)
MVA-BN standard regimen + MVA-BN standard regimen (Administered as PEP) is a phase 3 stage product being developed by Bavarian Nordic for Neonate. The current trial status is active. This product is registered under clinical trial identifier NCT06844500. Target conditions include Neonate, Maternal Transmission, Mpox.
What happened to similar drugs?
0 of 1 similar drugs in Neonate were approved
Approved (0) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
17
Activity
12
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06844500 | Phase 3 | Active |
Competing Products
1 competing product in Neonate
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Dexmedetomidine | Orion Corporation | Phase 3 | 37 |